Dewpoint Therapeutics Announces DPTX3496 as a Development Candidate for the Treatment of Colorectal, Breast, and Lung Cancers

Dewpoint Therapeutics’ second development candidate, DPTX3496 is an oral, small molecule acting via a novel condensate-modulating mechanism of action for the treatment of Wnt-driven cancersDPTX3496 shows robust tumor regression and stasis in pre-clinical animal models of colorectal, breast, and lung cancerDPTX3496 is currently in IND-enabling studies and IND filing is planned for the second half of 2025 BOSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Dewpoint Therapeutics Inc. – the leading biotechnology company ...